US cGMP vs EU GMP
The two GMP regimes a global supply chain has to satisfy at once.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
US current Good Manufacturing Practice lives in 21 CFR Parts 210 and 211, enforced by the FDA. EU GMP lives in EudraLex Volume 4 — a guide plus a set of Annexes — enforced by national competent authorities. Both are PIC/S-aligned and share the same intent, but the structure, the role of the Qualified Person, and batch release differ.
| ASPECT | US CGMP | EU GMP |
|---|---|---|
| Where it lives | Regulation: 21 CFR 210 (general) + 211 (finished pharmaceuticals) | Guidance: EudraLex Vol. 4 chapters + Annexes (given legal force via directives) |
| Batch release | Quality unit approves release; no single named legal releaser | A Qualified Person (QP) certifies each batch before release — a personal legal duty |
| Sterile / specialised areas | Covered within 211 + FDA guidance documents | Detailed Annexes (e.g., Annex 1 sterile, Annex 11 computerised, Annex 15 qualification) |
| Structure | Prescriptive regulation, supplemented by guidance | Principle-based guide with specialised Annexes |
| Harmonisation | PIC/S participating authority; ICH member | PIC/S participating authorities; ICH members |
| Inspections | FDA (or via MRA reliance) | National competent authority; EU-US MRA allows mutual reliance |
| Stability / specs | ICH-aligned (Q1, Q6, etc.), applied under 211 | ICH-aligned, applied under Vol. 4 |
Follow 21 CFR 210/211 (and FDA guidance) for product destined for the US market, and expect FDA inspection against the regulation text.
Follow EudraLex Vol. 4 and the relevant Annexes for product destined for the EU, and staff the QP role — there is no US analogue, and the QP’s batch certification is a hard legal gate.
The intent is the same and ICH/PIC/S keep them close, so a well-run site rarely runs two quality systems. The differences that actually bite are structural: the EU’s Qualified Person and personal batch certification, the EU Annex system (Annex 1 especially), and the fact that US cGMP is regulation while EU GMP is guidance given legal force. Design once to the stricter of the two, then handle the QP and Annex specifics per market.
US cGMP vs EU GMP: frequently asked questions
Common questions on how US cGMP and EU GMP differ and when each applies.
Are US cGMP and EU GMP equivalent?
They are closely aligned — both are PIC/S- and ICH-based, and the EU–US Mutual Recognition Agreement lets each rely on the other’s inspections — but they are not identical. The biggest structural difference is the EU Qualified Person’s personal certification of each batch, which has no US equivalent.
What is a Qualified Person (QP)?
In the EU, a QP is a named, legally responsible individual who certifies that every batch was manufactured and tested per the marketing authorisation and GMP before it is released. US cGMP assigns release to the quality unit but names no equivalent personal legal role.
Do I need to follow both?
If you supply both markets, yes — but you build one quality system to the stricter requirement and add market-specific elements (the QP and EU Annexes for the EU; FDA-specific expectations for the US), rather than operating two parallel systems.
Which is stricter?
Neither is uniformly stricter; they differ by area. EU Annex 1 sets very detailed sterile-manufacturing expectations, while some FDA guidance and enforcement expectations are more prescriptive in other areas. Sound practice designs to the stricter requirement in each domain.